Skip to main content
SpringerLink
Log in

Paper one: Resource allocation in cancer medicine: Invest where the benefits are clear

  • Main Feature
  • Fair And Effective Resource Allocation In Cancer Care: Uncharted Territory?
  • Published:
Health Care Analysis Aims and scope Submit manuscript

Conclusions

The future clearly lies in restricting the introduction of new treatments into medical practice unless they are beneficial and an improvement over existing compounds, together with a stepwise re-evaluation of current therapies. The days of analogue development which give 10% or 15% improvement in toxicity over existing compounds are no longer acceptable, and resources should be preserved for real advances. These may require support in their development, particularly at the randomised controlled trial level, by government or research institutions in collaboration with industry.

Patients in general are now better informed by their physicians, nurse specialists and self-help groups, although few regions have gone as far as Oregon in information dissemination and involvement of patients in resource allocation decisions. We should take comfort from the fact that in spite of all the difficulty, new treatments continue to be developed, reflecting a commitment from the public, government and the private sector for continued progress. The way forward may be challenging, but the medical profession has to demonstrate leadership by countering the short-sightedness and over-regulation which has resulted from the recent economic recession. We should be seen to be acting with foresight in maintaining the quest for real improvement in the best interests of patients. Governments in turn have a responsibility to ensure they maintain independent bodies of professionals who have the qualities of flexibility, critical ability and vision to ensure continued development of high quality care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weatherall, D.J. (1994). The inhumanity of medicine.British Medical Journal 308, 1671–1672.

    Google Scholar 

  2. McVie, J.G. (1988). Counting costs of care.Journal of Clinical Oncology,6, 1529–1531.

    Google Scholar 

  3. Markman, M. (1988). An argument in support of cost-effectiveness analysis in oncology.Journal of Clinical Oncology 6, 937–939.

    Google Scholar 

  4. Smith, T. J. G., Hillner, B. E. and Desche, C. E. (1993). Efficacy and cost-effectiveness of cancer treatment: national allocations of resources based on decision analysis.Journal of National Cancer Institute 85, 1460–1471.

    Google Scholar 

  5. Smith, T. J. G. and Hillner, B. E. (1993). The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.Journal of Clinical Oncology 11(4), 771–776.

    Google Scholar 

  6. Rice, D. P., Hodgson, T. A., and Capel, F. (1989). The economic burden of cancer 1985: United States and California. In,Cancer Care and Cost, ed. by R. M. Scheffler and N. C. Andrews, Health Administration Press, Ann Arbor.

    Google Scholar 

  7. Beardsley, T. (1994). A war not won: trends in cancer epidemiology.Scientific American,123.

  8. Kievit, J. and van de Valde, C. J. H. (1990). Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis.Cancer 65, 2580–2587.

    Google Scholar 

  9. Levine, M.N., Drummond, M.F. and Labelle, R.J. (1985). Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin.Canadian Medical Association Journal 133, 977–983.

    Google Scholar 

  10. Verhoef, L. C., Stalpers, L. J., Verbeck, A. L.et al. (1991). Breast-conserving treatment or mastectomy in early breast cancer: a clinical decision analysis with special reference to the risk of local recurrence.European Journal of Cancer 27, 1132–1137.

    Google Scholar 

  11. Wodinsky, H. B., De Angelis, C., Rusthoven, J. J.et al. (1987). Re-evaluating the cost of outpatient cancer chemotherapy.Canadian Medical Association Journal 137, 903–906.

    Google Scholar 

  12. Wodinsky, H.B. and Jenkin, R.D.T. (1987). The cost of radiation treatment at an Ontario regional treatment centre.Canadian Medical Association Journal 137, 906–909.

    Google Scholar 

  13. Murray, C. J., De Jongh, E., Chum, H. J., Nyangulu, D.S., Salomao, A. and Styblo, K. (1991). Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries.Lancet 338(87780), 1305–1308.

    Google Scholar 

  14. The Gusto Investigators (1993). An international randomised trial comparing four thrombolytic strategies for actute myocardial infarction.New England Journal of Medicine 329(10), 673–682.

    Google Scholar 

  15. Shibley, L., Brown, M., Schuttinga, J.et al. (1990). Cisplatin based combination chemotherapy in the treatment of advanced stage testicular cancer.Journal of National Cancer Institute 82, 186–192.

    Google Scholar 

  16. Welch, H.G. and Larson, E.B. (1989). Cost effectiveness of bone marrow transplantation in acute non-lymphocytic leukaemia.New England Journal of Medicine 321, 807–812.

    Google Scholar 

  17. Desch, C.E., Lasala, M.R., Smith, T.J.et al. (1992). The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients following a chemotherapy relapse.Journal of Clinical Oncology 10, 200–209.

    Google Scholar 

  18. Desch, C. E., Hillner, B. E., Smith, T. J. and Retchin, S. M. (1993). Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.Journal of Clinical Oncology 11(4), 777–782.

    Google Scholar 

  19. Brown, M. I., Mayfield, S. G. and Shibley, L. M. (1994). Adjuvant therapy for stage III colon cancer: economics returns to research.Journal of National Cancer Institute 86(6), 424–430.

    Google Scholar 

  20. Rajagopal, S., Goodman, P. J. and Tannock, I. F. (1994). Adjuvant chemotherapy for breast cancer: discordance between physicians perception of benefit and the results of clinical trials.Journal of Clinical Oncology 12(6), 1296–1304.

    Google Scholar 

  21. Slevin, M. L., Stubbs, L., Plant, H. J., Wilson, P., Gregory, W. M., Armes, P. J. and Downer, S. M. (1990). Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public.British Medical Journal 300(6737), 1458–1460.

    Google Scholar 

  22. Rees, G. J. G. (1985). Cost-effectiveness in oncology.Lancet 2, 1405–1408.

    Google Scholar 

  23. Rubens, R. D. (1990). Auditing palliative cancer chemotherapy.Eur. J. Cancer 26(10), 1023–1025.

    Google Scholar 

  24. Jaakkimainen, L., Goodwin, P. J., Pater, J., Warde, P., Murray, N. and Rapp, E. (1990). Counting the costs of chemotherapy in a National Cancer Institute of Canada.Journal of Clinical Oncology 8(8), 1301–1309.

    Google Scholar 

  25. Cox, F. and Hirsch, J. (1993). Ondansetron: a costeffective advance in anti-emetic therapy.Oncology 50(3), 186–190.

    Google Scholar 

  26. Zagonel, V., Babare, R., Merola, M. C., Talamini, R., Lazzarini, R., Tirella, U., Carbone, A. and Monfardini, S. (1994).Annals of Oncology 5(2), 127–132.

    Google Scholar 

  27. Nichols, C. R., Fox E. P., Roth, B. J., Williams, S. D., Lochner, P. J. and Einhorn, C. H. (1994). Incidence of neutropenic fever in patients treated with standard dose combination chemotherapy for small cell lung cancer and the cost impact of treatment with granulocyte colony stimulating factor.Journal of Clinical Oncology 12(6). 1245–1250.

    Google Scholar 

  28. Rosenshein, M. S., Farewell, V. T., Price, T. H.et al. (1980). The cost effectiveness of therapeutic and prophylactic leukocyte transfusion.New England Journal of Medicine.302, 1058–1062.

    Google Scholar 

  29. Green, J. A. (1992). Response in oncology (editorial).American Journal of Medicine 73, 779–780.

    Google Scholar 

  30. Hoel, D.G., Davis, D.L., Miller, A.B. et al (1992). Trends in cancer mortality in 15 industrialized countries, 1969–1986.Journal of National Cancer Institute 84, 313–320.

    Google Scholar 

  31. Cross, A. S. (1994). Anti-endotoxin antibodies: a dead end?Annals of Internal Medicine 121, 58–59.

    Google Scholar 

  32. Levi, F., Franceschi, S., La Vecchia, C., Renzicka, J., Gloor, E. and Randimibison, L. (1993). Epidemiologic pathology of ovarian cancer from the Vaud Registry, Switzerland.Annals of Oncology 4, 289–294.

    Google Scholar 

  33. Boyle, P., Soukop, M., Scully, C., Gerard Robertson, A., Burns, H. J. G., Gillis, C. R. and Kaye, S. B. (1988). Improving prognosis of Hodgkin's Disease in Scotland.European Journal of Cancer and Clinical Oncology 24, 229–234.

    Google Scholar 

  34. Weinstein, M. C. and Stason, W. B. (1982). Cost effectiveness of coronary artery bypass surgery.Circulation 66 (Suppl. 111), 56–65.

    Google Scholar 

  35. Edelson, J. T., Weinstein, M. C., Tosteson, A. N.et al. (1990). Long term cost effectiveness of various initial monotherapies for mild to moderate hypertension.Journal of the American Medical Association 263, 407–413.

    Google Scholar 

  36. Garner, T. and Dandis, R. (1987). Cost effectiveness analysis of end stage renal disease treatments.Medical Care 25, 25–34.

    Google Scholar 

  37. Schulman, K. A., Lynn, L. A. Glick, H. A.et al. (1991). Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with HIV infection.Annals of Internal Medicine.114, 798–802.

    Google Scholar 

  38. Concorde Co-ordinating Committee (1994). Concorde MRC/ANRS randomised double blind controlled trial of immediate and deferred Zidovudine in symptom free HIV infection.Lancet 343, 871–881.

    Google Scholar 

  39. Scrip's Yearbook (1994). PJB Publications Ltd, London.

  40. Gill, T. M. and Feinstein, A. R. (1994). A critical appraisal of quality of life measurement.Journal of the American Medical Association 272, 619–626.

    Google Scholar 

  41. Beatson, G. T. (1896). On the treatment of inoperable cases of carcinoma of the mamma suggestions for a new treatment.Lancet, 11 July, 104–107.

    Google Scholar 

  42. Jordan, V. C. (1995). What if tamoxifen (ICI 46,474) has been found to produce rat liver tumours in 1993.Annals of Oncology 6, 29–34.

    Google Scholar 

  43. HMSO (1992).The Health of the Nation: A Strategy for Health in England, CM 1986.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Liverpool, P.O. Box 147, L69 3BX, Liverpool

    John A. Green (Senior Lecturer in Medical Oncology)

Authors
  1. John A. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, J.A. Paper one: Resource allocation in cancer medicine: Invest where the benefits are clear. Health Care Anal 4, 19–28 (1996). https://doi.org/10.1007/BF02251142

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02251142

Keywords

Search

Navigation